STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

Estimated average burden
OMB Number:			3235-0287
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopfner Robert Lorne

(Last)

(First)

(Middle)

C/O EVOMMUNE, INC.

1841 PAGE MILL ROAD, SUITE 100

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/07/2025		C		3,026	A	⁽¹⁾	3,026	I	By Trust⁽²⁾
Common Stock	11/07/2025		C		1,441,032	A	⁽¹⁾⁽³⁾⁽⁴⁾⁽⁵⁾	1,441,032	I	By NFLS Delta III Limited⁽⁶⁾
Common Stock	11/07/2025		C		1,632,441	A	⁽¹⁾⁽³⁾⁽⁴⁾⁽⁵⁾	1,632,441	I	By Pivotal bioVenture Partners Fund I, L.P.⁽⁷⁾
Common Stock	11/07/2025		C		294,502	A	⁽⁵⁾	294,502	I	By Pivotal bioVenture Partners Fund II, L.P.⁽⁸⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**
**(e.g., puts, calls, warrants, options, convertible securities)**
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series Seed Preferred Stock	⁽¹⁾	11/07/2025		C			25,790	⁽¹⁾	⁽¹⁾	Common Stock	3,026	⁽¹⁾	0	I	By Trust⁽²⁾
Series Seed Preferred Stock	⁽¹⁾	11/07/2025		C			7,145,647	⁽¹⁾	⁽¹⁾	Common Stock	838,886	⁽¹⁾	0	I	By NFLS Delta III Limited⁽⁶⁾
Series Seed Preferred Stock	⁽¹⁾	11/07/2025		C			3,572,816	⁽¹⁾	⁽¹⁾	Common Stock	419,441	⁽¹⁾	0	I	By Pivotal bioVenture Partners Fund I, L.P.⁽⁷⁾
Series A Preferred Stock	⁽³⁾	11/07/2025		C			2,582,243	⁽³⁾	⁽³⁾	Common Stock	324,578	⁽³⁾	0	I	By NFLS Delta III Limited⁽⁶⁾
Series A Preferred Stock	⁽³⁾	11/07/2025		C			7,230,283	⁽³⁾	⁽³⁾	Common Stock	908,821	⁽³⁾	0	I	By Pivotal bioVenture Partners Fund I, L.P.⁽⁷⁾
Series B Preferred Stock	⁽⁴⁾	11/07/2025		C			1,895,260	⁽⁴⁾	⁽⁴⁾	Common Stock	240,756	⁽⁴⁾	0	I	By NFLS Delta III Limited⁽⁶⁾
Series B Preferred Stock	⁽⁴⁾	11/07/2025		C			2,104,740	⁽⁴⁾	⁽⁴⁾	Common Stock	267,367	⁽⁴⁾	0	I	By Pivotal bioVenture Partners Fund I, L.P.⁽⁷⁾
Series C Preferred Stock	⁽⁵⁾	11/07/2025		C			313,571	⁽⁵⁾	⁽⁵⁾	Common Stock	36,812	⁽⁵⁾	0	I	By NFLS Delta III Limited⁽⁶⁾
Series C Preferred Stock	⁽⁵⁾	11/07/2025		C			313,571	⁽⁵⁾	⁽⁵⁾	Common Stock	36,812	⁽⁵⁾	0	I	By Pivotal bioVenture Partners Fund I, L.P.⁽⁷⁾
Series C Preferred Stock	⁽⁵⁾	11/07/2025		C			2,508,575	⁽⁵⁾	⁽⁵⁾	Common Stock	294,502	⁽⁵⁾	0	I	By Pivotal bioVenture Partners Fund II, L.P.⁽⁸⁾

Explanation of Responses:

1. Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

2. The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

3. Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

4. Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

5. Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

6. Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

7. Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

8. Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

	/s/ Gregory S. Moss, Attorney-in-Fact	11/12/2025
	** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

4: Statement of changes in beneficial ownership of securities

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP